chig...Ifida deserves the credit for digging that one up.
There were many things I found fascinating about the presentation. I'll list a few here:
- Dalton talked about how they had been putting this together for better than a year (Gabriel said they had been working on the Moffitt collaboration for about 1-1/2 years).
- In describing the spherical graphic that explained the interrelation of all the program elements (minute 25 of the video) he mentioned that the Model was originally developed by Jim Fiorica for Ovarian Cancer, and that he adapted it to fit all cancers for the Total Cancer Care Initiative (we know from the Ovanome Executive Summary and Tony's TWST article that Ovanome was in clinical trial from late 2002 into the summer of 2003, we just don't know where).
- Dalton alluded to the NIH, and discussed the need for the program to address the economies, as well as, the benefits associated with a personalized medicine approach. That we can't simply throw Fort Knox at one patient (in the way of treatment and testing costs), without showing how you pay for that. I can envision DNAPrint having had this same argument with NIH or FDA regarding the utility of their tests. I am very excited at the prospect that DNAPrint, with Moffitt as a collaborator, will get the opportunity to DEMONSTRATE the economies of a personalized approach to medicine, which should help pave the way for regulatory approval for reimbursement from insurance plans and medicare when their tests become a routine element in medical prescription practice.
- Dalton referred over and over again to "evidence-based" medicine. No more shotgun approach. Along these lines, he referred on more than one occasion to a population based approach to the cancer therapies and he credited "the sequencing of the Human Genome" for making such an approach possible. Nothing earth shattering in these thoughts, just very well aligned with what DNAPrint has been saying for several years.
- Lastly, I found the reference to "smart cards" fascinating. I remember Tony Frudakis talking about this years ago when describing his vision of personalized medicine? I know there were and are others with similar thoughts. Just thought it was VERY cool to see it here.
"Moffitt scientists and physicians were impressed with DNAPrint's ADMIXMAP approach for using a population's structure as a fuel for mapping drug response gene variants. We recognized its profound potential for contributing to the enhancement of cancer treatment," said Moffitt's Dr. Timothy Yeatman.
Yep, I get more comfortable with my investment every day...
Later,
W2P
